ID   CRMi001-A-1
AC   CVCL_UG26
SY   CRMi001-A-1-CLTA-TQ2; NCRM-5-CLTA-TQ2; SANFi002-A-1
DR   hPSCreg; CRMi001-A-1
DR   Wikidata; Q93458788
RX   PubMed=30340091;
CC   From: NIH Center for Regenerative Medicine (CRM); Bethesda; USA.
CC   Characteristics: Using CRISPR/Cas9 CTLA has been endogenously tagged in one allele at the C-terminus with a mTurquoise2-P2A-PuroR construct (PubMed=30340091).
CC   Genetic integration: Method=CRISPR/Cas9; Gene=FPbase; 7AV5G; mTurquoise2 (Note=Tq2, cyan fluorescent protein derived from GFP).
CC   Genetic integration: Method=CRISPR/Cas9; Gene=UniProtKB; P13249; S.alboniger pac (PuroR).
CC   Derived from site: In situ; Umbilical cord blood; UBERON=UBERON_0012168.
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_1E75 ! NCRM-5
SX   Male
AG   <1D
CA   Induced pluripotent stem cell
DT   Created: 13-11-18; Last updated: 10-09-24; Version: 8
//
RX   PubMed=30340091; DOI=10.1016/j.scr.2018.10.001; PMCID=PMC6383648;
RA   Anderson R.H., Kerkvliet J.G., Otta J.J., Ross A.D., Leiferman P.C.,
RA   Hoppe A.D., Francis K.R.;
RT   "Generation of a CLTA reporter human induced pluripotent stem cell
RT   line, CRMi001-A-1, using the CRISPR/Cas9 system to monitor endogenous
RT   clathrin trafficking.";
RL   Stem Cell Res. 33:95-99(2018).
//